CXCL9 and neoplasm: Using a series of in vitro migration assays, Amatschek et al. showed that melanoma cells can migrate towards the CXCL9 gradients created by tumour endothelial cells and through endothelial monolayers, a process accelerated by additional soluble CXCL9.